Literature DB >> 12470608

Differentiation of human gamma-delta T cells towards distinct memory phenotypes.

Matthias Eberl1, Rosel Engel, Ewald Beck, Hassan Jomaa.   

Abstract

Vgamma9/Vdelta2 T cells comprise a small population of peripheral T cells responding towards the low molecular weight antigen, (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate (HMB-PP). HMB-PP-stimulated Vgamma9/Vdelta2 T cells proliferated, expressed CCL5/RANTES, and upregulated markers like CD16, CD25, CD69, and CD94, in the presence of either IL-15 or IL-21. Vgamma9/Vdelta2 T cells grown in the presence of IL-15 differentiated into an effector/memory population characterized by production of TNF-alpha, expression of CD45RO and CCR5, and lack of CD62L, CD81, and CCR7. In contrast, Vgamma9/Vdelta2 T cells grown with IL-21 differentiated into putative central memory CD45RO(+) T cells that did not produce TNF-alpha, IFN-gamma, or IL-4, and maintained expression of CD62L, CD81, and CCR7.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12470608     DOI: 10.1016/s0008-8749(02)00519-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  24 in total

1.  Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells.

Authors:  Matthias Eberl; Hassan Jomaa; Adrian C Hayday
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 2.  IL-17 family member cytokines: regulation and function in innate immunity.

Authors:  Joseph M Reynolds; Pornpimon Angkasekwinai; Chen Dong
Journal:  Cytokine Growth Factor Rev       Date:  2010-11-11       Impact factor: 7.638

3.  Characterization of avian γδ T-cell subsets after Salmonella enterica serovar Typhimurium infection of chicks.

Authors:  Jana Pieper; Ulrich Methner; Angela Berndt
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

4.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

5.  Circulating gamma delta T cells in response to Salmonella enterica serovar enteritidis exposure in chickens.

Authors:  Angela Berndt; Jana Pieper; Ulrich Methner
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 6.  γδ-T cells: an unpolished sword in human anti-infection immunity.

Authors:  Jian Zheng; Yinping Liu; Yu-Lung Lau; Wenwei Tu
Journal:  Cell Mol Immunol       Date:  2012-10-15       Impact factor: 11.530

7.  Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.

Authors:  David Vermijlen; Peter Ellis; Cordelia Langford; Anne Klein; Rosel Engel; Katharina Willimann; Hassan Jomaa; Adrian C Hayday; Matthias Eberl
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

8.  IL-21 promotes the development of a CD73-positive Vγ9Vδ2 T cell regulatory population.

Authors:  Clément Barjon; Henri-Alexandre Michaud; Angeline Fages; Cécile Dejou; Alexandre Zampieri; Laetitia They; Aurélie Gennetier; Françoise Sanchez; Laurent Gros; Jean-François Eliaou; Nathalie Bonnefoy; Virginie Lafont
Journal:  Oncoimmunology       Date:  2017-10-04       Impact factor: 8.110

9.  Analysis of circulating gammadelta T cells in children affected by IgE-associated and non-IgE-associated allergic atopic eczema/dermatitis syndrome.

Authors:  C Cairo; E Arabito; F Landi; A Casati; E Brunetti; G Mancino; E Galli
Journal:  Clin Exp Immunol       Date:  2005-07       Impact factor: 4.330

Review 10.  Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses.

Authors:  Pallavur V Sivakumar; Donald C Foster; Christopher H Clegg
Journal:  Immunology       Date:  2004-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.